Bimekizumab – a monoclonal antibody that inhibits both interleukin (IL)-17A and IL-17F – has shown promise in phase 3 trials across the spectrum of spondyloarthritis. Take a look at this page for a quick-reference summary of the data in psoriatic arthritis and axial spondyloarthritis, expert opinion on what the trial results might mean for clinical practice, and the latest news on research and regulatory approvals.
Joseph Merola talks about the BE COMPLETE and BE OPTIMAL trials, which showed that the dual IL-17A/IL-17F inhibitor bimekizumab is a promising treatment option for psoriatic arthritis patients with and without prior exposure to TNF inhibitors.
Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape if approved by the regulatory authorities.
The results of two phase 3 studies suggest that dual inhibition of IL-17A and IL-17F with bimekizumab may represent a promising treatment option for nonradiographic axial spondyloarthritis and ankylosing spondylitis.
Follow-up results from the BE ACTIVE and BE AGILE phase 2b trials show that the efficacy and safety profiles of bimekizumab are maintained for up to 3 years in patients with psoriatic arthritis or ankylosing spondylitis.